Possible Teratogenic Effects of Imipramine in the Rat

  • C. L. DeVane
  • J. W. Simpkins
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 3)


Tricyclic antidepressants are sometimes used during pregnancy (Crombie et al. 1972; Scanlon 1969). In reviews of studies which examine the teratogenic potential of antidepressants in humans it is frequently concluded that these drugs are relatively safe for use in pregnant patients (Calabrese and Gulledge 1985; Csernansky and Hollister 1984). While ethical and experimental restraints prohibit a thorough assessment of the results of prenatal drug exposure in humans, animal experiments have indicated that physiologic, biochemical, and behavioral effects may result from in utero drug exposure. Collectively, our pharmacokinetic and dynamic studies indicate that third trimester administration of imipramine (IMI) to rats in doses that do not cause dysmorphic effects in the fetus results in substantial fetal drug and metabolite exposure, enhances infant mortality, and has teratogenic effects persisting into adulthood on neuronal systems which regulate growth and reproductive function. These data imply that maternal ingestion of imipramine may result in subclinical teratogenic effects, which may not be evident, if at all, until offspring have matured past adolescence.


Luteinizing Hormone Estrous Cycle Teratogenic Effect Estradiol Benzoate Female Progeny 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brodie BB, Costa E, Dlabec A, Neff NH, Smookler HW (1966) Application of steady state kinetics to the stimulation of synthesis rate and turnover time of tissue catecholamines. J Pharmacol Exp Ther 154: 493–498PubMedGoogle Scholar
  2. Calabrese JR, Gulledge AD (1985) Psychotropics during pregnancy and lactation: a review. Psychosomatics 26: 413–426PubMedGoogle Scholar
  3. Crombie D, Pinsent RJ, Felming D (1972) Imipramine in pregnancy. Br Med J 1:745Google Scholar
  4. Csernansky JG, Hollister LE (1984) Psychotropic medications: the risk of teratogenesis. Hosp Formul Manage 19: 718–723Google Scholar
  5. DeVane CL, Simpkins JW (1985) Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. Drug Metab Dispos 13: 438–442PubMedGoogle Scholar
  6. Scanlon FV (1969) Use of antidepressant drugs during the first trimester. Med J Aust 2: 1077PubMedGoogle Scholar
  7. Simpkins JW, Geagan GJ (1986) Teratogenic effects of late pregnancy exposure to imipramine in the rat. (submitted for publication)Google Scholar
  8. Simpkins JW, Field FP, Torosian G, Soltis EE (1985) Effects of prenatal exposure to tricyclic antidepressants on adrenergic responses in progeny. Dev Pharmacol Ther 8: 17–33PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • C. L. DeVane
    • 1
    • 3
  • J. W. Simpkins
    • 2
    • 3
  1. 1.Department of Pharmacy PracticeUniversity of FloridaGainesvilleUSA
  2. 2.Department of PsychiatryUniversity of FloridaGainesvilleUSA
  3. 3.Department of PharmacodynamicsUniversity of FloridaGainesvilleUSA

Personalised recommendations